Determination of Residual Anticoagulatory Effects of Fondaparinux

Determination of Residual Anticoagulatory Effects of Prophylactic or Therapeutic Treatment With Fondaparinux

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01101256

Enrollment

110

Registered

2010-04-09

Start date

2010-04-30

Completion date

2010-10-31

Last updated

2010-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anticoagulant Prophylaxis/Therapy

Brief summary

The purpose of this study is to determine residual anticoagulatory effects of a prophylactic or therapeutic fondaparinux treatment i.e. prior to surgery/intervention, after pause of therapy etc.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Fondaparinux therapy for at least 3 days

Exclusion criteria

* Age \< 18 years * Hemodialysis

Design outcomes

Primary

Measure	Time frame
antiXa-levels (peak- and through-levels)	between day 3 and day 14 after start of therapy

Secondary

Measure	Time frame
thromboembolic or bleeding episodes, HIT	day 14 after start of therapy

Countries

Germany

Contacts

Primary ContactMarc Schindewolf, MD

marcschindewolf@yahoo.com+49 (0)69 6301

Outcome results